Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Acquisitions & Divestments: 2015-2024

Historic Change in Acquisitions & Divestments for Viking Therapeutics (VKTX) over the last 10 years, with Dec 2024 value amounting to $560.0 million.

  • Viking Therapeutics' Change in Acquisitions & Divestments rose 3.18% to $181.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $786.9 million, marking a year-over-year increase of 43.14%. This contributed to the annual value of $560.0 million for FY2024, which is 87.16% up from last year.
  • Per Viking Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $560.0 million for FY2024, which was up 87.16% from $299.2 million recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Change in Acquisitions & Divestments peaked at $560.0 million during FY2024, and registered a low of $176.2 million during FY2022.
  • Its 3-year average for Change in Acquisitions & Divestments is $345.1 million, with a median of $299.2 million in 2023.
  • As far as peak fluctuations go, Viking Therapeutics' Change in Acquisitions & Divestments slumped by 36.07% in 2021, and later skyrocketed by 87.16% in 2024.
  • Over the past 5 years, Viking Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $322.2 million in 2020, then crashed by 36.07% to $206.0 million in 2021, then decreased by 14.46% to $176.2 million in 2022, then surged by 69.83% to $299.2 million in 2023, then spiked by 87.16% to $560.0 million in 2024.